FI60871C - Foerfarande foer framstaellning av terapeutiskt anvaendbara n-(5-tetrazolyl)-4-oxo-4h-pyrimido(2,1-b)benzotiazol-3-karboxamider - Google Patents
Foerfarande foer framstaellning av terapeutiskt anvaendbara n-(5-tetrazolyl)-4-oxo-4h-pyrimido(2,1-b)benzotiazol-3-karboxamider Download PDFInfo
- Publication number
- FI60871C FI60871C FI770848A FI770848A FI60871C FI 60871 C FI60871 C FI 60871C FI 770848 A FI770848 A FI 770848A FI 770848 A FI770848 A FI 770848A FI 60871 C FI60871 C FI 60871C
- Authority
- FI
- Finland
- Prior art keywords
- oxo
- pyrimido
- tetrazolyl
- benzothiazole
- aminotetrazole
- Prior art date
Links
- -1 5-TETRAZOLYL Chemical class 0.000 title claims description 31
- 230000001225 therapeutic effect Effects 0.000 title description 3
- 230000035764 nutrition Effects 0.000 title 1
- 235000016709 nutrition Nutrition 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 29
- ULRPISSMEBPJLN-UHFFFAOYSA-N 2h-tetrazol-5-amine Chemical compound NC1=NN=NN1 ULRPISSMEBPJLN-UHFFFAOYSA-N 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 14
- SZXLBDVCHABEGD-UHFFFAOYSA-N 2h-1,3-benzothiazole-3-carboxamide Chemical class C1=CC=C2N(C(=O)N)CSC2=C1 SZXLBDVCHABEGD-UHFFFAOYSA-N 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 239000000460 chlorine Substances 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 54
- 238000006243 chemical reaction Methods 0.000 description 25
- 239000000203 mixture Substances 0.000 description 19
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 239000000725 suspension Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- 206010020751 Hypersensitivity Diseases 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 206010002198 Anaphylactic reaction Diseases 0.000 description 10
- 230000036783 anaphylactic response Effects 0.000 description 10
- 208000003455 anaphylaxis Diseases 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 229940027941 immunoglobulin g Drugs 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- PIINGSXUWUVNKU-UHFFFAOYSA-N 4-oxopyrimido[2,1-b][1,3]benzothiazole-3-carboxylic acid Chemical class S1C2=CC=CC=C2N2C1=NC=C(C(=O)O)C2=O PIINGSXUWUVNKU-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 4
- 230000003266 anti-allergic effect Effects 0.000 description 4
- 239000000043 antiallergic agent Substances 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000009610 hypersensitivity Effects 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229940124630 bronchodilator Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229960003699 evans blue Drugs 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- CYXIKYKBLDZZNW-UHFFFAOYSA-N 2-Chloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)CCl CYXIKYKBLDZZNW-UHFFFAOYSA-N 0.000 description 2
- IVRZHCPGPPBIHN-UHFFFAOYSA-N 4-oxo-n-(2h-tetrazol-5-yl)pyrimido[2,1-b][1,3]benzothiazole-3-carboxamide Chemical compound C=1N=C2SC3=CC=CC=C3N2C(=O)C=1C(=O)NC1=NN=NN1 IVRZHCPGPPBIHN-UHFFFAOYSA-N 0.000 description 2
- OPZWXOQCGAIDCA-UHFFFAOYSA-N 7,8-dimethoxy-4-oxo-n-(2h-tetrazol-5-yl)pyrimido[2,1-b][1,3]benzothiazole-3-carboxamide Chemical compound O=C1N2C=3C=C(OC)C(OC)=CC=3SC2=NC=C1C(=O)NC=1N=NNN=1 OPZWXOQCGAIDCA-UHFFFAOYSA-N 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960000265 cromoglicic acid Drugs 0.000 description 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 230000000521 hyperimmunizing effect Effects 0.000 description 2
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 2
- 150000007928 imidazolide derivatives Chemical class 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- RZXMPPFPUUCRFN-UHFFFAOYSA-N p-toluidine Chemical compound CC1=CC=C(N)C=C1 RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- QBIWKKPKTMGYOE-UHFFFAOYSA-N 1-(2h-tetrazol-5-yl)-10ah-pyrimido[2,1-b][1,3]benzothiazol-4-one Chemical class C12SC3=CC=CC=C3N2C(=O)C=CN1C1=NN=NN1 QBIWKKPKTMGYOE-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- VZXOZSQDJJNBRC-UHFFFAOYSA-N 4-chlorobenzenethiol Chemical compound SC1=CC=C(Cl)C=C1 VZXOZSQDJJNBRC-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- AXBVSRMHOPMXBA-UHFFFAOYSA-N 4-nitrothiophenol Chemical compound [O-][N+](=O)C1=CC=C(S)C=C1 AXBVSRMHOPMXBA-UHFFFAOYSA-N 0.000 description 1
- QICMOJDQOUBODS-UHFFFAOYSA-N 4-oxo-7-propan-2-yloxy-N-(2H-tetrazol-5-yl)pyrimido[2,1-b][1,3]benzothiazole-3-carboxamide Chemical compound O=C1N2C3=CC(OC(C)C)=CC=C3SC2=NC=C1C(=O)NC=1N=NNN=1 QICMOJDQOUBODS-UHFFFAOYSA-N 0.000 description 1
- MAAPDMSZJODJJW-UHFFFAOYSA-N 7,8-dimethoxy-4-oxopyrimido[2,1-b][1,3]benzothiazole-3-carboxylic acid Chemical compound S1C2=NC=C(C(O)=O)C(=O)N2C2=C1C=C(OC)C(OC)=C2 MAAPDMSZJODJJW-UHFFFAOYSA-N 0.000 description 1
- VZDWBNBKYCHXFV-UHFFFAOYSA-N 7-ethoxy-4-oxo-n-(2h-tetrazol-5-yl)pyrimido[2,1-b][1,3]benzothiazole-3-carboxamide Chemical compound O=C1N2C3=CC(OCC)=CC=C3SC2=NC=C1C(=O)NC=1N=NNN=1 VZDWBNBKYCHXFV-UHFFFAOYSA-N 0.000 description 1
- CKQROPPYIBPWHP-UHFFFAOYSA-N 7-fluoro-4-oxo-n-(2h-tetrazol-5-yl)pyrimido[2,1-b][1,3]benzothiazole-3-carboxamide Chemical compound O=C1N2C3=CC(F)=CC=C3SC2=NC=C1C(=O)NC=1N=NNN=1 CKQROPPYIBPWHP-UHFFFAOYSA-N 0.000 description 1
- ZSPGIMOADOHZRX-UHFFFAOYSA-N 8-chloro-4-oxopyrimido[2,1-b][1,3]benzothiazole-3-carboxylic acid Chemical compound S1C2=CC(Cl)=CC=C2N2C1=NC=C(C(=O)O)C2=O ZSPGIMOADOHZRX-UHFFFAOYSA-N 0.000 description 1
- LKIZXVVDPBXIOJ-UHFFFAOYSA-N 8-fluoro-4-oxo-n-(2h-tetrazol-5-yl)pyrimido[2,1-b][1,3]benzothiazole-3-carboxamide Chemical compound C=1C(F)=CC=C(N2C3=O)C=1SC2=NC=C3C(=O)NC=1N=NNN=1 LKIZXVVDPBXIOJ-UHFFFAOYSA-N 0.000 description 1
- KRDBHKSHUOTOFU-UHFFFAOYSA-N 8-methoxy-4-oxo-n-(2h-tetrazol-5-yl)pyrimido[2,1-b][1,3]benzothiazole-3-carboxamide Chemical compound C=1C(OC)=CC=C(N2C3=O)C=1SC2=NC=C3C(=O)NC=1N=NNN=1 KRDBHKSHUOTOFU-UHFFFAOYSA-N 0.000 description 1
- BPXGVDLTYDVZDZ-UHFFFAOYSA-N 8-methoxy-4-oxopyrimido[2,1-b][1,3]benzothiazole-3-carboxylic acid Chemical compound C1=C(C(O)=O)C(=O)N2C3=CC=C(OC)C=C3SC2=N1 BPXGVDLTYDVZDZ-UHFFFAOYSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- KCRSTPXSIZXTHF-UHFFFAOYSA-N C(=O)(O)C1=CN=C2SC3=C(N2C1=O)C=C(C(=C3)OCC)OCC Chemical compound C(=O)(O)C1=CN=C2SC3=C(N2C1=O)C=C(C(=C3)OCC)OCC KCRSTPXSIZXTHF-UHFFFAOYSA-N 0.000 description 1
- WFZKRNIMSVDNBU-UHFFFAOYSA-N Creatinine sulfate mixture with serotonin Chemical compound [O-]S([O-])(=O)=O.C[NH+]1CC(=O)N=C1N.C1=C(O)C=C2C(CC[NH3+])=CNC2=C1 WFZKRNIMSVDNBU-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methyl-N-phenylamine Natural products CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 150000007930 O-acyl isoureas Chemical class 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010070774 Respiratory tract oedema Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000794 anti-serotonin Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- RGBMMOMUOWOGBF-UHFFFAOYSA-N benzo[g][2,1]benzothiazole Chemical compound C1=CC=C2C3=NSC=C3C=CC2=C1 RGBMMOMUOWOGBF-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000004044 bronchoconstricting agent Substances 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 229960000645 histamine hydrochloride Drugs 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical compound CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- WHMDPDGBKYUEMW-UHFFFAOYSA-N pyridine-2-thiol Chemical class SC1=CC=CC=N1 WHMDPDGBKYUEMW-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/671,030 US4041163A (en) | 1976-03-29 | 1976-03-29 | N-(5-Tetrazolyl)-4-oxo-4H-pyrimido(2,1-b)benzothiazole-3-carboxamide antiallergy agents |
| US67103076 | 1976-03-29 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI770848A FI770848A (de) | 1977-09-30 |
| FI60871B FI60871B (fi) | 1981-12-31 |
| FI60871C true FI60871C (fi) | 1982-04-13 |
Family
ID=24692862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI770848A FI60871C (fi) | 1976-03-29 | 1977-03-17 | Foerfarande foer framstaellning av terapeutiskt anvaendbara n-(5-tetrazolyl)-4-oxo-4h-pyrimido(2,1-b)benzotiazol-3-karboxamider |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US4041163A (de) |
| JP (1) | JPS52118497A (de) |
| AR (1) | AR215886A1 (de) |
| AT (1) | AT355030B (de) |
| BE (1) | BE852485A (de) |
| BG (1) | BG27757A3 (de) |
| CA (1) | CA1079276A (de) |
| CH (1) | CH606019A5 (de) |
| CS (1) | CS198236B2 (de) |
| DD (1) | DD130247A5 (de) |
| DE (1) | DE2712079C3 (de) |
| DK (1) | DK146160C (de) |
| ES (1) | ES456944A1 (de) |
| FI (1) | FI60871C (de) |
| FR (1) | FR2346357A1 (de) |
| GB (2) | GB1560923A (de) |
| GR (1) | GR72695B (de) |
| HU (1) | HU173643B (de) |
| IE (1) | IE44031B1 (de) |
| IL (1) | IL51616A (de) |
| LU (1) | LU76970A1 (de) |
| NL (1) | NL166945C (de) |
| NO (1) | NO150044C (de) |
| NZ (1) | NZ183634A (de) |
| PH (1) | PH12757A (de) |
| PL (1) | PL103466B1 (de) |
| PT (1) | PT66321B (de) |
| RO (1) | RO71888A (de) |
| SE (1) | SE436570B (de) |
| SU (1) | SU784782A3 (de) |
| YU (1) | YU40669B (de) |
| ZA (1) | ZA771485B (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2810863A1 (de) * | 1978-03-13 | 1979-09-27 | Boehringer Mannheim Gmbh | 1-oxo-1h-pyrimido eckige klammer auf 6,1-b eckige klammer zu benzthiazol-derivate und verfahren zu ihrer herstellung |
| US4223031A (en) * | 1978-05-05 | 1980-09-16 | Mead Johnson & Company | Azolopyrimidinones |
| US4491587A (en) * | 1978-05-05 | 1985-01-01 | Mead Johnson & Company | Tetrazole derivatives |
| US4230707A (en) * | 1979-08-27 | 1980-10-28 | Warner-Lambert Company | Oxo-pyrido[1,2-a]thienopyrimidine compounds and methods for their production |
| US4282360A (en) * | 1979-10-12 | 1981-08-04 | Hoffmann-La Roche Inc. | 7-Methylthio or methylsulfinyl-5-oxo-5H-thiazolo[2,3-b]quinazoline-2-carboxylic acid |
| DK151811C (da) * | 1979-11-23 | 1988-06-06 | Pfizer | Analogifremgangsmaade til fremstilling af n-(5-tetrazolyl)-1-oxo-1h-thiazolooe3,2-aaa-pyrimidin-2-carboxamider eller farmaceutisk acceptable kationsalte deraf samt 1-oxo-1h-thiazolooe3,2-aaapyrimidin-2-carboxylsyrer til anvendelse som udgangsmaterialer ved fremgangsmaaden |
| US4423048A (en) * | 1979-11-23 | 1983-12-27 | Pfizer Inc. | Antiallergic and antiulcer 1-oxo-1H-thiazolo[3,2-a]pyrimidine-2-carboxamides and intermediates therefor |
| US4535081A (en) * | 1979-11-23 | 1985-08-13 | Pfizer Inc. | Antiallergic and antiulcer 1-oxo-1H-thiazolo[3,2-a]pyrimidine-2-carboxamides and intermediates therefor |
| US4414388A (en) * | 1979-11-23 | 1983-11-08 | Pfizer Inc. | 1-Oxo-1H-thiazolo[3,2-a]pyrimidine-2-carboxamides |
| US4443451A (en) * | 1981-07-15 | 1984-04-17 | Janssen Pharmaceutica N.V. | Bicyclic pyrimidin-5-one derivatives |
| DE3208218A1 (de) * | 1982-03-06 | 1983-09-08 | Basf Ag, 6700 Ludwigshafen | Isoindolinfarbstoffe und deren verwendung |
| GB8300728D0 (en) * | 1983-01-12 | 1983-02-16 | Erba Farmitalia | Substituted carboxy-thiazolo / 3 2 - a / pyrimidine derivatives |
| JPS59163735U (ja) * | 1983-04-14 | 1984-11-02 | モリタ工業株式会社 | 家庭用風呂釜の給排気管装置 |
| US4457932A (en) * | 1983-07-22 | 1984-07-03 | Bristol-Myers Company | Anti-ulcer agents |
| US4762840A (en) * | 1984-02-13 | 1988-08-09 | Roussel Uclaf | Pyrimido[2,1-b]benzothiazoles having antiallergic activity |
| US4879295A (en) * | 1986-09-27 | 1989-11-07 | Sawai Pharmaceutical Co., Ltd. | N-tetrazolyl thiazolecarboxyamide derivatives and their use |
| US5063228A (en) * | 1990-05-31 | 1991-11-05 | A. H. Robbins Company, Incorporated | 4-(substitutedaminoethyl)-3,4-dihydro-2-alkylpyrimido[1,6-a]benzimidazol-1(2H)-ones as antiarrhythmic agents |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH491944A (de) * | 1966-11-29 | 1970-06-15 | Ciba Geigy | Verfahren zur Herstellung von benzheterocyclischen Verbindungen |
-
1976
- 1976-03-29 US US05/671,030 patent/US4041163A/en not_active Expired - Lifetime
- 1976-12-07 IE IE2675/76A patent/IE44031B1/en unknown
-
1977
- 1977-02-11 GB GB5759/77A patent/GB1560923A/en not_active Expired
- 1977-03-01 SE SE7702272A patent/SE436570B/xx not_active IP Right Cessation
- 1977-03-07 NO NO770782A patent/NO150044C/no unknown
- 1977-03-07 IL IL51616A patent/IL51616A/xx unknown
- 1977-03-08 PH PH19544A patent/PH12757A/en unknown
- 1977-03-11 ZA ZA00771485A patent/ZA771485B/xx unknown
- 1977-03-14 CA CA273,886A patent/CA1079276A/en not_active Expired
- 1977-03-15 BE BE1008009A patent/BE852485A/xx not_active IP Right Cessation
- 1977-03-15 GR GR52996A patent/GR72695B/el unknown
- 1977-03-16 YU YU682/77A patent/YU40669B/xx unknown
- 1977-03-17 DK DK118277A patent/DK146160C/da not_active IP Right Cessation
- 1977-03-17 AT AT183877A patent/AT355030B/de not_active IP Right Cessation
- 1977-03-17 DE DE2712079A patent/DE2712079C3/de not_active Expired
- 1977-03-17 NZ NZ183634A patent/NZ183634A/xx unknown
- 1977-03-17 FI FI770848A patent/FI60871C/fi not_active IP Right Cessation
- 1977-03-17 NL NL7702895.A patent/NL166945C/xx not_active IP Right Cessation
- 1977-03-17 FR FR7708035A patent/FR2346357A1/fr active Granted
- 1977-03-17 CH CH337077A patent/CH606019A5/xx not_active IP Right Cessation
- 1977-03-17 ES ES456944A patent/ES456944A1/es not_active Expired
- 1977-03-18 LU LU76970A patent/LU76970A1/xx unknown
- 1977-03-18 JP JP3024077A patent/JPS52118497A/ja active Granted
- 1977-03-18 PT PT66321A patent/PT66321B/pt unknown
- 1977-03-22 BG BG7735760A patent/BG27757A3/xx unknown
- 1977-03-23 AR AR266945A patent/AR215886A1/es active
- 1977-03-25 RO RO7789795A patent/RO71888A/ro unknown
- 1977-03-28 SU SU772465654A patent/SU784782A3/ru active
- 1977-03-28 HU HU77PI569A patent/HU173643B/hu unknown
- 1977-03-29 CS CS772079A patent/CS198236B2/cs unknown
- 1977-03-29 DD DD7700198118A patent/DD130247A5/de unknown
- 1977-03-29 PL PL1977197000A patent/PL103466B1/pl unknown
- 1977-05-10 GB GB19542/77A patent/GB1516964A/en not_active Expired
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI60871C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara n-(5-tetrazolyl)-4-oxo-4h-pyrimido(2,1-b)benzotiazol-3-karboxamider | |
| DK2844637T3 (en) | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS BY SSAO AND USES THEREOF | |
| USRE42152E1 (en) | Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity | |
| DK160279B (da) | Analogifremgangsmaade til fremstilling af 3-(1h-tetrazol-5-yl)-4h-pyrido(1,2-a)pyrimidin-4-on-derivater | |
| DK172690B1 (da) | Analogifremgangsmåde til fremstilling af salte af sulfodehydroabietinsyre eller hydrater deraf | |
| PL199783B1 (pl) | Związki pochodne chinolino-3-karboksyamidu, zawierające je kompozycje farmaceutyczne, sposób ich wytwarzania i ich zastosowanie | |
| CZ20003849A3 (cs) | Deriváty chinolinu | |
| JP2008501021A (ja) | Ｈｉｖインテグラーゼ阻害剤としての二環式複素環 | |
| IE840655L (en) | 1,3-thiazolidine derivatives | |
| CS249115B2 (en) | Method of new imidazolylphenylamides production | |
| SK319892A3 (en) | N-phenyl-2-cyano-3-hydroxycrotonamide derivatives, method of their poduction and their using for manufacture of medicines with immunomodulating effect | |
| EP2464354B1 (de) | Pyrimido-pyrrolo-chinoxalindionhemmer des regulatorproteins für die transmembranen-leitfähigkeit zystischer fibrose und verwendungen davon | |
| SK82098A3 (en) | Biologically active benzothiazolone ethanamines | |
| JPS62265270A (ja) | 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤 | |
| KR960016123B1 (ko) | 디-t-부틸페닐 알킬 및 벤질 에테르류 | |
| KR900003649B1 (ko) | (1H-테트라졸-5-일)테트라졸로[1,5-a]-퀴놀린의 제조방법 | |
| CS207499B2 (en) | Method of making the heterocyclic aminopyrimidine compounds | |
| CS195731B2 (en) | Process for preparing n-/5-tetrazolyl/-1-oxo-1h-6-alkoxypyrimido/1,2-a/quinolin-2-carboxamides | |
| IE54441B1 (en) | 3-(1h-tetrazol-5-yl)-4(3h)-quinazolinones | |
| RU2143429C1 (ru) | ПРОИЗВОДНЫЕ 6-(2-ИМИДАЗОЛИНИЛАМИНО)ХИНОЛИНА И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, ОБЛАДАЮЩАЯ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ α--2-АДРЕНОРЕЦЕПТОРОВ | |
| EP0143461A2 (de) | Rhodanin-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen die sie enthalten | |
| CS241476B2 (en) | Method of substituted n-5-tetrazolyl-1-oxo-1h-thiazolo- (3,2-a )pyrimidine-2-carboxamides production | |
| AU727216B2 (en) | Sulfonamide-substituted compounds, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them | |
| SU1452481A3 (ru) | Способ получени гетероциклических соединений | |
| KR800001139B1 (ko) | N-(5-테트라졸릴)-4-옥소-4H-피리미도[2,1-b]벤조티아졸류의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: PFIZER INC. |